AKT1 and neoplasm: Our strategy was to minimize the heterodimerization of HER2 receptor and inhibit the downstream signaling pathways (RAS-RAF-MEK-ERK MAPK and AKT-PI3K-mTOR) for cell proliferation, survival, and tumor growth (Fig. 1).